| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| A714 | Genentech anti-BACE1 Featured |
|
|
| A715 | U.Toronto patent anti-Bax Featured |
|
|
| A716 | XmAb 5592 Featured | XmAb 5592 is a humanized, Fc-engineered anti-HM1.24 antibody with enhanced binding to FcγRIIIa and FcγRIIa receptors, augments HM1.24-specific multiple myeloma (MM) cells lysis in vitro via antibody-dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). |
|
| A717 | SBI Biotech patent anti-BST2 Featured |
|
|
| A718 | Icatolimab Featured |
|
|
| A719 | ICT-01 Featured |
|
|
| A720 | CTX-2026 Featured |
|
|
| A721 | ICT-01-N297A Featured |
|
|
| A722 | ANX005 Featured |
|
|
| A723 | Sutimlimab Featured | Sutimlimab, a first-in-class complement protein component 1, s subcomponent (C1s) inhibitor, can be used for the research of cold agglutinin disease. C1s is a serine protease which cleaves C4 and C2 to form the C3 convertase. |
|
| A725 | Eptinezumab Featured | Eptinezumab is a humanized monoclonal antibody. Eptinezumab binds to calcitonin gene-related peptide (CGRP) and blocks its interaction with the receptor. Eptinezumab is used for the prevention of migraine in adults. |
|
| A726 | Galcanezumab Featured | Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody against the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research. |
|
| A727 | Fremanezumab Featured | Fremanezumab (TEV-48125) is a humanized IgG2a monoclonal antibody that selectively and potently binds to calcitonin gene-related peptide (CGRP). CGRP is a 37-amino acid neuropeptide involved in central and peripheral pathophysiological events of migraine. Fremanezumab has the potential for chronic migraine research. |
|
| A728 | Erenumab Featured | Erenumab is a fully human monoclonal antibody. Erenumab inhibits the calcitonin gene–related peptide (CGRP) receptor. Erenumab can be used for the prevention of episodic migraine. |
|
| A729 | Toray patent anti-Caprin-1 Featured |
|
|
| A730 | Nimacimab Featured |
|
|
| A731 | GFB-024 Featured |
|
|
| A732 | Carlumab Featured | Carlumab (CNTO 888) is a human anti-CCL2 (chemokine ligand 2) antibody with high affinity. Carlumab can be used in cancer research, particularly in prostate cancer. |
|
| A733 | GSK-3050002 (E-6071) Featured |
|
|
| A734 | FG-3019 Featured | FG-3019 (Pamrevlumab) is a recombinant human antibody that binds to connective tissue growth factor (CTGF). FG-3019 can be used for the research of idiopathic pulmonary fibrosis (IPF). |
|
| A735 | Plozalizumab Featured | Plozalizumab (MLN-1202) is a specific humanized anti-CCR2 antibody. Plozalizumab can be used for malignant melanoma research. |
|
| A736 | Ivonescimab Featured | Ivonescimab (AK112) is a PD-1/VEGF Bispecific Antibody. Ivonescimab can be used for cancer research. |
|
| A737 | Leronlimab Featured | Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer. |
|
| A738 | Atibuclimab Featured | Atibuclimab, is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab can be used for the research of amyotrophic lateral sclerosis. Atibuclimab attenuates LPS-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. |
|
| A739 | Pierre Fabre patent anti-CD151 Featured |
|
|
| A740 | Anti-CD163 Antibody (OR2805) Featured |
|
|
| A741 | Tafasitamab Featured | Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19. |
|
| A742 | Inebilizumab Featured | Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research. |
|
| DC67117 | 113-N16B Featured | 113-N16B is an ionizable cationic lipid used for the generation of lipid nanoparticles (LNPs). 113-N16B delivers mRNA preferentially to pulmonary endothelial cells. |
|
| DC67119 | VC1052 | VC1052 is the component of HY-142998 Vaxfectin. Vaxfectin is a cationic lipid-based adjuvant that can be used for plasmid DNA- and protein-based vaccines. |
|
